The biology of combination immunotherapy in recurrent metastatic head and neck cancer
Abstract
Preclinical data suggest that head and neck cancer is an intrinsically immunosuppressive disease with abnormal inflammatory components in the tumor microenvironment. The development of immune checkpoint inhibitors, which are monoclonal antibodies capable of inhibiting immune suppressive signals to prime anticancer immunity, has revolutionized the therapeutic landscape in recurrent/metastatic head and neck cancer. However, patients with head and neck cancer present primary resistance to immunotherapy. Many ongoing trials include combinations of immunotherapy with different therapeutic interventions, aiming to improve response rates and overall survival. As novel therapy strategies are leveraged, the significance of immunotherapy in recurrent/metastatic head and neck cancer continues to be revealed. This review aims to summarize combinational immunotherapy in head and neck cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, STING agonist, FMT, epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity.
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [29]
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336 · see citing works
Pignon, J., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,066 · see citing works
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823 · see citing works
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · see citing works
Lydiatt, W. M., Patel, S. G., O’Sullivan, B., Brandwein, M. S., Ridge, J. A., Migliacci, J. C., Loomis, A. M., & Shah, J. P. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21389 · Cited by 1,626 · see citing works
Cohen, E., Soulières, D., le Tourneau, C., Dinis, J., Licitra, L., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,423 · see citing works
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.12.017 · Cited by 1,210 · see citing works
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works
Self-citationRadiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H. L., Deng, L., & Fu, Y. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,073 · see citing works
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · see citing works
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845 · see citing works
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777 · see citing works
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 776 · see citing works
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 756 · see citing works
Self-citationCohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B. A., Gillison, M. L., Harrington, K. J., Le, Q., Lee, N. Y., Leidner, R. S., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 719 · see citing works
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works
Self-citationImmunology and Immunotherapy of Head and Neck Cancer
Ferris, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1509 · Cited by 668 · see citing works
Bauml, J. M., Seiwert, T. Y., Pfister, D. G., Worden, F. P., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L. J., Sukari, A. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 662 · see citing works
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608 · see citing works
Self-citationExosomes and tumor-mediated immune suppression
Whiteside, T. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81136 · Cited by 570 · see citing works
Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 549 · see citing works
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514 · see citing works
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works
Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490 · see citing works
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388 · see citing works
Radiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 367 · see citing works
Taylor, M., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C., Wu, J., Stepan, D., Shumaker, R., & Motzer, R. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 327 · see citing works
Siu, L. L., Even, C., Mesı́a, R., Remenár, É., Daste, A., Delord, J., Krauß, J., Saba, N. F., Nabell, L. M., Ready, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4628 · Cited by 308 · see citing works
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306 · see citing works
Self-citationCompetition for nutrients and its role in controlling immune responses
Kedia-Mehta, N., & Finlay, D. K. (2019) · Nature Communications · doi:10.1038/s41467-019-10015-4 · Cited by 287 · see citing works
Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Draghiciu, O., Lubbers, J. M., Nijman, H. W., & Daemen, T. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954829 · Cited by 274 · see citing works
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 265 · see citing works
Self-citationThe role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221 · see citing works
Self-citationChen, Y.-B., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M., Le, Q., Lee, N. Y., Colevas, A., Seiwert, T., Hayes, D. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 217 · see citing works
Komiya, T., & Huang, C. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00423 · Cited by 187 · see citing works
Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01135.x · Cited by 184 · see citing works
Yamasaki, K., Horiguchi, S., Kurosaki, M., Kunii, N., Nagato, K., Hanaoka, H., Shimizu, N., Ueno, N., Yamamoto, S., Taniguchi, M., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.11.014 · Cited by 183 · see citing works
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works
Self-citationUchida, T., Horiguchi, S., Tanaka, Y., Yamamoto, H., Kunii, N., Motohashi, S., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0373-5 · Cited by 168 · see citing works
Davis, R. J., Waes, C. V., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 165 · see citing works
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Rasmussen, J. H., Lelkaitis, G., Håkansson, K., Vogelius, I. R., Johannesen, H. H., Fischer, B. M., Bentzen, S. M., Specht, L., Kristensen, C. A., von Buchwald, C., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0449-y · Cited by 165 · see citing works
Bergmann, C., Strauss, L., Wang, Y., Szczepański, M. J., Lang, S., Johnson, J. T., & Whiteside, T. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5126 · Cited by 156 · see citing works
<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works
Self-citationPD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dolan, D. E., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100308 · Cited by 144 · see citing works
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works
Self-citationOweida, A. J., Lennon, S., Calame, D. J., Korpela, S. P., Bhatia, S., Sharma, J., Graham, C., Binder, D. C., Serkova, N. J., Raben, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356153 · Cited by 128 · see citing works
Srivastava, R. M., Trivedi, S., Concha‐Benavente, F., Gibson, S. P., Reeder, C., Ferrone, S., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0879 · Cited by 121 · see citing works
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96 · see citing works
Self-citationTumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
Qin, Y., Zheng, X., Gao, W., Wang, B., & Wu, Y. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.011 · Cited by 75 · see citing works
Zhu, G., Tang, Y., Geng, N., Zheng, M. H., Jiang, J. D., Li, L., Li, K., Lei, Z., Chen, W., Fan, Y., et al. (2014) · Neoplasia · doi:10.1593/neo.132034 · Cited by 73 · see citing works
Faden, D. L., Ding, F., Lin, Y., Zhai, S., Kuo, F., Chan, T. A.-T., Morris, L. G. T., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.07.020 · Cited by 59 · see citing works
Matoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 54 · see citing works
Checkpoint immunotherapy in head and neck cancers
Zolkind, P., & Uppaluri, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9694-9 · Cited by 52 · see citing works
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2020) · Cancers · doi:10.3390/cancers12113377 · Cited by 48 · see citing works
Licitra, L. F., Haddad, R. I., Even, C., Tahara, M., Dvorkin, M. V., Ciuleanu, T., Clement, P., Mesı́a, R., Кутукова, С. И., Zholudeva, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6012 · Cited by 37 · see citing works
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 34 · see citing works
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 29 · see citing works
Self-citationAlimohammadi, R., Alibeigi, R., Nikpoor, A. R., Chalbatani, G. M., Webster, T. J., Jaafari, M. R., & Jalali, S. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s260760 · Cited by 27 · see citing works
Saleh, K., Daste, A., Martin, N., Tostivint, E. P., Auperin, A., Gómez, R. G. H., Basté, N., Bidault, F., Guigay, J., Tourneau, C. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6015 · Cited by 25 · see citing works
Strauss, J., Gatti-Mays, M. E., Redman, J. M., Madan, R. A., Lamping, E., Manu, M., Burmeister, A., Marté, J. L., Cordes, L. M., Ojalvo, L. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3007 · Cited by 22 · see citing works
Mell, L. K., Torres‐Saavedra, P. A., Wong, S. J., Chang, S., Kish, J. A., Minn, A. J., Jordan, R. C., Liu, T., Truong, M. T., Bauman, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6065 · Cited by 19 · see citing works
Strauss, J., Gatti-Mays, M. E., Cho, B., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Lamping, E., Burmeister, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct075 · Cited by 16 · see citing works
Ren, Y., Geng, R., Lu, Q., Tan, X., Rao, R., Zhou, H. W., Yang, X., & Liu, W. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s238145 · Cited by 15 · see citing works
The 5-Ws of immunotherapy in head and neck cancer
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Rocco, C. D., Amirhassankhani, S., Sirgiovanni, G., Occhipinti, M. A., Napoli, V. M., Emiliani, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103041 · Cited by 15 · see citing works
Rassy, E. E., Assi, T., Bakouny, Z., Karak, F. E., Pavlidis, N., & Ghosn, M. (2019) · Future Oncology · doi:10.2217/fon-2018-0663 · Cited by 11 · see citing works
Nagarsheth, N., Norberg, S. M., Doran, S. L., Kanakry, J. A., Adhikary, S., Schweitzer, C., Astrow, S. H., Faquin, W. C., Gkitsas-Long, N., Highfill, S. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3043 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Self-citationYi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163 · see citing works
Self-citationImmune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 122 · see citing works
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01487-5 · Cited by 106 · see citing works
Self-citationHigh Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies
Ghiani, L., & Chiocca, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073483 · Cited by 40 · see citing works
The role of immune checkpoint molecules in cancers
Zhang, M., Xu, J., Zheng, Z., Guo, Z., Wang, H., Zhou, M., Tang, H., & Zhu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1674818 · Cited by 8 · see citing works
Zhang, W., Qu, M., Yin, C., Jin, Z., & Hu, Y. N. (2024) · Discover Oncology · doi:10.1007/s12672-024-00921-5 · Cited by 2 · see citing works
Self-citationImmune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2 · see citing works
Bradford, C. R., Sreeram, M. P., Rao, K. N., Guntinas‐Lichius, O., Saba, N. F., & Ferlito, A. (2026) · Head & Neck · doi:10.1002/hed.70385 · Cited by 1 · see citing works
Current Advances in Immune Checkpoint Therapy
Russell, B. L., Malindisa, S. T., Sooklal, S. A., & Ntwasa, M. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.107315 · Cited by 1 · see citing works
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26610165
Self-citationApplication of mRNA vaccines in head and neck cancer immunotherapy: Current progress and challenges
Wu, L., Liu, H., Wang, Z., Yan, J., Xu, K., Dong, Y., Zhu, Z., Xiang, Y., & Zhang, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105501
Proximal Proteomics Reveals Potential Regulators of Programmed Death-Ligand 1 in Human Cancer
Shi, F., Liu, D., Liu, Y., Li, F., Zhang, C. Z., Li, Q., & Tian, Q. (2026) · ACS Omega · doi:10.1021/acsomega.6c06622
- Authors
- Yuan, X., Yi, M., Zhang, W., Xu, L., Chu, Q., Luo, S., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Luo, Suxia
- Wu, Kongming
- Venue
- The International Journal of Biochemistry & Cell Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 136
- Pages
- 106002
- ISSN
- 1357-2725 (ISSN-L)
- OpenAlex
- W3157045289
- Cited by
- 13
- References
- 71
- Citations by year
- 2026: 4 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 1
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The International Journal of Biochemistry & Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
- Keywords
- combination immunotherapy, immune checkpoint inhibitors, tumor microenvironment, immunosuppression, antitumor immunity, tumor inflammatory microenvironment
- MeSH terms
- Squamous Cell Carcinoma of Head and Neck, Animals, Head and Neck Neoplasms, Humans, Immunotherapy, Neoplasm Recurrence, Local, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
